Michelle Alleva: The Long Way Home - a detrans journey
Michelle Alleva: autistic, traumatised, 21. Clinics handed her testosterone, mastectomy, hysterectomy—never asked why she hurt. A decade later she’s detrans and sounding the alarm: the affirmation model is creating casualties.
نمای کلی
Michelle Alleva, an autistic and ADHD woman, began medical transition at 21 after a lifetime of feeling “different.” With no exploration of her neurodivergence, trauma, or emerging borderline-personality traits, she was fast-tracked onto testosterone, underwent a double-mastectomy, and later a hysterectomy. Five years off hormones and deep self-reflection led her to detransition in 2021; she now warns that the affirmation-only model fails vulnerable patients and predicts a coming wave of detransitioners.
خلاصه کامل ویدیو
Michelle Alleva’s story begins in 2010, when, at 21, she first encountered the idea that her lifelong discomfort with femininity might mean she was “trans.” Growing up undiagnosed autistic and ADHD, she had always felt “different,” bullied for being gender-nonconforming and overwhelmed by the sensory and social demands of girlhood. No one—least of all Michelle—linked her distress to neurodivergence. Instead, an online message-board post asking, “Have you ever questioned your gender?” offered a new, ready-made narrative: perhaps she was “genderqueer,” then FTM (female-to-male) transgender. Within a year she had adopted a male name, joined a Toronto support group run by trans-identified therapists, and accepted one of the first “informed-consent” referrals to testosterone that bypassed the city’s longer psychiatric gate-keeping pathway. The medical transition unfolded quickly: testosterone began October 2010, a double-mastectomy followed in January 2012, and a partial hysterectomy was completed in 2018. Yet Michelle now questions whether she ever gave informed consent. She points out that no clinician explored her autism, ADHD, history of sexual trauma, or the emotional volatility that would later earn her a borderline-personality-disorder diagnosis. The pre-transition “40 questions” booklet she was handed, she recalls, asked only leading, identity-affirming questions (“What do you dislike about being female?”) rather than hard ones like, “Are you prepared for the possibility the world may still read you as female?” She believes the affirmation-only model allowed her to interpret normal adolescent tomboyishness, sensory aversions to bras and lace, and post-abusive-relationship body-disgust as proof she was “really a man.” Five years before she officially detransitioned, Michelle quietly stopped testosterone because she could no longer tolerate the injections, the acne, and the emotional numbing. Living as a non-passing “trans guy,” she remained active in Tumblr-based social-justice circles where identity status doubled as social currency; straight, white trans men, she notes, were still dismissed as “privileged.” The turning point came when the disability-advocacy group she wrote for was “cancelled” over its use of the word “Asperger’s.” Experiencing the same black-and-white dehumanization she had once doled out, she began to see the parallel between cancel culture and the bullying she survived in childhood. Watching her roommate—also a detransitioner with BPD—emerge from the “fog” of trans identification further cracked her conviction. In 2021 she finally admitted to herself that the decade-long attempt to escape femaleness had been, in her words, “another form of escapism,” and she began writing publicly under the handle “Some Nuance Please.” Today Michelle lives free of cross-sex hormones, antidepressants, and marijuana, and she reports the return of emotional range, crying, and an internal sense that “the pre-T persona stepped back into the driver’s seat.” She accepts that strangers will sometimes still read her as male, but her well-being no longer depends on controlling their perception. On her Substack she argues that rising numbers of detransitioners are inevitable and urges clinicians to replace cosmetic gate-keeping (“Did you wear a dress to the appointment?”) with exploratory therapy that asks, “Where is the dysphoria coming from?” She frames her own story less as a cautionary tale about transgender medicine than as a case study in how unexamined autism, trauma, personality-disorder traits, and social-justice ideology can converge to make medical transition feel like the only imaginable form of relief—until it isn’t.